Regeneron says its COVID-19 monoclonal antibody has been authorized in Europe


Shares of Regeneron Pharmaceuticals Inc. were down 0.2% in trading on Friday after the company said its monoclonal antibody cocktail has been authorized in Europe, both as a treatment and to prevent COVID-19 in cases when someone has been exposed to the virus. The cocktail is called Regen-Cov in the U.S., where it is authorized, and Ronapreve in Europe, where it can now be used in individuals who are at least 12 years old with confirmed cases of COVID-19 and who are at high risk of severe disease. The treatment is authorized in about 40 countries, including Australia, the U.K., and India. Regeneron’s stock is up 29.4%…

This article was originally published by Read the original article here.

Previous articleThe Margin: No, you can’t ‘undo’ a COVID vaccine with a borax bath — but you could hurt yourself
Next article: What the U.N. climate talks got right and wrong, according to a fund manager and a climate-risk researcher


Please enter your comment!
Please enter your name here